The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer

BACKGROUND: Triple negative breast cancer (TNBC) is not sensitive to RAS/RAF/ERK signaling pathway (ERK pathway) targeting therapy, due to the absence of excessive activation of ERK pathway. However, the kinase cascades might be activated after chemotherapy in TNBC. Here we aimed to predict whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jianbo, Luo, Qingqing, Xiao, Yun, Li, Hongyuan, Kong, Lingquan, Ren, Guosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746140/
https://www.ncbi.nlm.nih.gov/pubmed/29296238
http://dx.doi.org/10.18632/oncotarget.22604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746140/
https://www.ncbi.nlm.nih.gov/pubmed/29296238
http://dx.doi.org/10.18632/oncotarget.22604

Ejemplares similares